A cohort study analyzed data from the Vellore CVT Registry in India, involving nearly 2,500 adult CVT patients (median age 34, 53% women) enrolled between 2000 and 2024.
96% of patients survived the acute phase, with a mean follow-up of 3.2 years; 70% completed 1-year follow-up, and 26% were followed for over 5 years.
Acute treatment included low-molecular-weight heparin (74%) or unfractionated heparin (25%), followed by oral anticoagulants (82%) or novel OACs (7%).
92% of patients achieved functional independence (mRS ≤ 2) within 2 years.
Overall mortality was 2%, with 58.5% of deaths occurring within the first year and 24% within the first 3 months.
33.5% of patients developed complications, with 51% requiring rehospitalization; 55% of complications occurred more than 2 years post-diagnosis.
Seizures affected 10% of patients, with risk factors including midline shift (OR 2.55), herniation (OR 2.5), focal seizures (OR 1.6), and generalized seizures (OR 2.1).
New-onset headaches were reported in 8% of patients.
Bleeding complications occurred in 4%, with 84% happening during anticoagulation; risk factors included baseline anemia, OCP use, and female sex.
Recurrent CVT developed in 1% of patients after a mean of 64 months, with OCP use linked to a 2.7-fold increased risk.
Malignancies developed in 1% of patients at a median of 50 months, and dural arteriovenous fistulas (DAVFs) in 1%.
Among women with subsequent pregnancies, 3% experienced thrombotic events.
The study was led by Sanjith Aaron, MD, at Christian Medical College, Vellore, and published in the *International Journal of Stroke* on February 17.
Limitations included variable follow-up, potential biases from the ambispective design, and the tertiary care setting.

A large cohort study from India’s Vellore CVT Registry, involving nearly 2,500 adult patients with cerebral venous sinus thrombosis (CVT), found that 92% achieved functional independence (mRS ≤ 2) within two years. While 96% survived the acute phase, 2% died during follow-up, with most deaths occurring within the first year. However, 33.5% of patients experienced long-term complications, including seizures (10%), headaches (8%), and bleeding events (4%), with over half of these complications arising more than two years post-diagnosis. Risk factors for seizures included midline shift, herniation, and seizure type, while bleeding risks were higher in women, those with baseline anemia, and users of oral contraceptive pills (OCPs). Recurrent CVT occurred in 1% of patients, with OCP use increasing recurrence risk. The study highlights the need for long-term surveillance, as complications often emerge years after initial treatment, challenging the assumption that CVT is a short-term condition.
The research, led by Sanjith Aaron, MD, at Christian Medical College, Vellore, spanned 24 years and combined retrospective and prospective data. Treatment primarily involved anticoagulants, with 82% receiving oral anticoagulants and 7% novel OACs. Limitations include potential biases from the ambispective design, variable follow-up, and the tertiary care setting, which may underrepresent milder cases. The findings underscore the importance of structured follow-up but may not fully generalize to other healthcare systems.

**Steelman:** This study provides robust, long-term data on CVT outcomes, challenging the notion that recovery is straightforward. The high rate of functional independence (92%) is encouraging, but the significant burden of late complications—seizures, headaches, bleeding—demonstrates that CVT is not a one-time event but a chronic condition requiring vigilance. The identification of risk factors (e.g., OCP use, anemia) offers actionable insights for clinicians. The study’s scale (2,500 patients over 24 years) and rigorous follow-up lend credibility to its findings, even if generalizability is limited by its single-center, tertiary care design.
**Pattern Scan:** The narrative leans toward a "good news, but..." framing, which is structurally sound but risks overshadowing the severity of late complications. The emphasis on functional recovery might inadvertently downplay the 33.5% complication rate, a classic case of **ARC-0012 Rosy Forecasting**—highlighting positive outcomes while relegating negative ones to secondary status. The discussion of limitations is thorough, avoiding **ARC-0024 Ambiguity**, but the tertiary care setting’s bias toward severe cases could skew perceptions of CVT’s typical trajectory.
**Root Cause:** The paradigm here is the tension between acute care success and long-term management. Modern medicine excels at saving lives in the short term (96% survival) but often struggles with chronic surveillance. The assumption that CVT is a "fixed" condition after initial treatment is being dismantled, echoing broader patterns in neurology where conditions like stroke or TBI reveal late sequelae only through prolonged follow-up.
**Implications:** For patients, this means lifelong monitoring, not just a discharge plan. For healthcare systems, it demands resources for long-term neurology care, which are often lacking. The cost burden shifts from acute intervention to chronic management, with women (especially OCP users) and those with anemia bearing disproportionate risks. The 1% recurrence rate may seem low, but for a rare condition, it’s a meaningful signal.
**Bridge Questions:** How might these findings change anticoagulation guidelines for CVT survivors? What structural barriers prevent long-term follow-up in non-tertiary settings? If OCP use is a modifiable risk factor for recurrence, should contraceptive counseling be standard post-CVT?
**Counterstrike Scan:** A bad-faith actor could weaponize this study to argue that CVT is "no big deal" (92% recovery!) while ignoring the complication rates, or conversely, to stoke fear by focusing solely on late risks. The actual content avoids this trap by presenting both outcomes clearly, though the "favorable prognosis" framing in the conclusion leans slightly toward reassurance. No structural alignment with manipulation playbooks detected—this appears to be a straightforward, if cautiously optimistic, clinical report.
**Patterns detected: ARC-0012 Rosy Forecasting (mild)**